CoChat

The microbiome and human cancer

Open access
Sepich-Poore, Gregory D., Zitvogel, Laurence, Straussman, Ravid, Hasty, Jeff, Wargo, Jennifer A., Knight, Rob · 2021 · Science

The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index; 65 of the 179 sources its claims cite were checked for support.

Abstract

BACKGROUND: Historical accounts linking cancer and microbes date as early as four millennia ago. After establishment of the germ theory of infectious diseases, clinical research of microbial influences on cancer began in 1868, when William Busch reported spontaneous tumor regressions in patients with Streptococcus pyogenes infections. Over the next century, poor reproducibility, erroneous microbiological claims, and severe toxicity led many to discount the role of bacteria in carcinogenesis and cancer therapy. However, these studies provided the first crude demonstrations of cancer immunotherapy. Contemporaneously, the viral theory of cancer flourished, spurred by the 1911 discovery of Rous sarcoma virus, which transformed benign tissue into malignant tumors in chickens. The decades-long search to find viruses behind every human cancer ultimately failed, and many cancers have been linked to somatic mutations. Now the field is encountering intriguing claims of the importance of microbes, including bacteria and fungi, in cancer and cancer therapy. This Review critically evaluates this evidence in light of modern cancer biology and immunology, delineating roles for microbes in cancer by examining advances in proposed mechanisms, diagnostics, and modulation strategies. ADVANCES: Few microbes directly cause cancer, but many seem complicit in its growth, often acting through the host’s immune system; conversely, several have immunostimulatory properties. Mechanistic analyses of gut microbiota–immune system interactions reveal powerful effects on antitumor immunity by modulating primary and secondary lymphoid tissue activities. Many of these pathways invoke Toll-like receptor–initiated cytokine signaling, but microbial metabolic effects and antigenic mimicry with cancer cells are also important. In preclinical models, microbial metabolites also regulate phenotypes of tumor somatic mutations and modulate immune checkpoint inhibitor efficacy. Emerging evidence suggests that intratumoral bacteria exist and are active, with overlapping immunohistochemistry, immunofluorescence, electron microscopy, and sequencing data in ~10 cancer types. Preliminary studies further suggest that fungi and bacteriophages contribute to gastrointestinal cancers. However, the abundance of intratumoral microbial cells is low relative to cancer cells, and knowledge of their functional repertoire and potency remains limited. Further validation of their prevalence and impact is needed in diverse cohorts and therapeutic contexts. The immunomodulatory effects of host microbiota have reinvigorated efforts to change their composition as a form of immunotherapy. Despite extensive preclinical evidence, translation of microbiota modulation approaches into humans has not yet materialized into commercialized therapies. Synthetic biology approaches are also gaining traction, with engineered bacterial cancer therapies in preclinical and clinical trial settings. OUTLOOK: A better understanding of the roles of microbes in cancer provides an opportunity to improve each stage of the cancer care cycle, but major challenges remain. Concerted efforts to characterize cancer-associated microbiota among tumor, stool, and blood samples with gold-standard contamination controls would tremendously aid this progress. This would be analogous to The Cancer Genome Atlas’s role in characterizing the cancer somatic mutation landscape. Large-scale clinical trials are currently testing the efficacy of microbiota modulation approaches, ranging from dietary modifications to intratumorally injected, engineered bacteria. These bacterial cancer therapies, if safe and effective, could tremendously expand the cancer therapy armamentarium. Altogether, integrating the host-centric and microbial viewpoints of cancer may improve patient outcomes while providing a nuanced understanding of cancer-host-microbial evolution. Opportunities for microbes to affect cancer care.: Diagnosis: Cancer-specific, blood-borne microbial DNA may complement cell-free tumor DNA (ctDNA). Prognosis: Gut and intratumoral microbiota may stratify patient outcomes (NR, nonresponder; R, responder; TME, tumor microenvironment). Therapy: Intratumor injection of CD47 nanobody (CD47nb)–producing Escherichia coli may create systemic antitumor immunity by enhancing dendritic cell (DC) phagocytosis, lymph node (LN) antigen (Ag) presentation, and cytotoxic T lymphocyte (CTL) activity.

Overview

Integrity signals

Registry

Crossref · 10.1126/science.abc4552

Cites

176 of 176 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

28 Valid · 4 Not valid · 64 Not checked · 22 Own results and interpretations

59 more claims · 12 with their cited sources checked

Create a free account to see all 118 claims and to verify the 114 references still open.

See all claims — free account
  • It may state two separate claims as one. 52
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

1 retracted

Show all 176 references

Research works printed but not linked: 2

  1. W. Busch, Aus der Sitzung der medicinischen Section vom 13 November 1867. Berl Klin Wochenschr 5, 137 (1868).
  2. T. J. Glover, The bacteriology of cancer. Canada Lancet Pract. 75, 92–111 (1930).

Cited by

Items 401–500 of 1,001

Metadata

Authors
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R.
Affiliations
  • Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA.
  • Université Paris-Sud (FR)
  • Weizmann Institute of Science (IL)
  • University of California San Diego (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Knight, Rob
Venue
Science
Published
2021-03-26
Volume
371
Issue
6536
Pages
91-97
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W3138215020
Cited by
1,332
References
176
Citations by year
2026: 231 · 2025: 310 · 2024: 294 · 2023: 274 · 2022: 161 · 2021: 62
FWCI
21.37
Type
journal article
Language
en
Open access
Locations
  • Science (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Cancer Institute (F30 CA243480, R01CA255206)
  • RHU Torino Lumière (ANR-16-RHUS-0008)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
microbiome, cancer, gut microbiota, antitumor immunity, microbial metabolites, Toll-like receptors, immune checkpoint inhibitors, intratumoral bacteria, bacteriophages, gastrointestinal cancer, cancer immunotherapy, microbiota modulation, engineered bacteria, Rous sarcoma virus, viral oncogenesis, molecular mimicry
MeSH terms
Gastrointestinal Microbiome, Host Microbial Interactions, Anti-Bacterial Agents, Antineoplastic Agents, Bacteria, Genetic Engineering, Humans, Immunotherapy, Lymphoid Tissue, Neoplasms, Virus Physiological Phenomena, Bacterial Physiological Phenomena, Oncolytic Virotherapy, Adaptive Immunity, Immunomodulation, Tumor Microenvironment, Carcinogenesis, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.